Whatever Glenmark wanted to prove by introducing Zitamed and ZIta, their new anti-diabetes drugs, they’ve definitely topped this season. Mumbai-based Glenmark Pharmaceuticals introduced the two anti-diabetes drugs in aRs 3,000-crore lucrative anti-diabetes market dominated by multinationals The drugmaker, which is locked in a bitter patent infringement battle with US drug firm Merck Sharp and Dohme’s